{"id":4217,"date":"2026-11-11T09:00:00","date_gmt":"2026-11-11T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4217"},"modified":"2026-11-11T20:45:28","modified_gmt":"2026-11-12T00:45:28","slug":"mediator-kinase-inhibition-sensitizes-aml-models-to-venetoclax","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4217","title":{"rendered":"Mediator Kinase Inhibition Sensitizes AML Models to Venetoclax"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Leukemia_Mediator_Kinase_Technology_and_Modalities-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4232\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Leukemia_Mediator_Kinase_Technology_and_Modalities-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Leukemia_Mediator_Kinase_Technology_and_Modalities-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Leukemia_Mediator_Kinase_Technology_and_Modalities-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Leukemia_Mediator_Kinase_Technology_and_Modalities-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261111_Leukemia_Mediator_Kinase_Technology_and_Modalities.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Academic investigators (Leukemia)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Leukemia)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Small molecule (preclinical)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>AML874<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CDK8\/19 (Mediator kinase module); BCL2 (combination)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Acute myeloid leukemia (FLT3-mutant subset)<\/p>\n<h4>Summary<\/h4>\n<p>A peer-reviewed Leukemia paper published online November 11 identifies CDK8\/19 Mediator kinase inhibition as an AML vulnerability and reports preclinical synergy with venetoclax. It does not establish patient efficacy.<\/p>\n<p>The study describes AML874 as a CDK8\/19 inhibitor, integrates compound-response and functional genomics, finds pronounced sensitivity in FLT3-mutant AML, and tests single-agent and combination activity in vivo.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> transcriptional disruption may complement BCL2 inhibition in a molecularly defined subset. Support: orthogonal target evidence and in-vivo combination testing. Against: model-system drug exposure and tolerability may differ in patients, and FLT3-mutant AML already has active targeted competitors.<\/p>\n<p><strong>Interpretation B:<\/strong> the synergy reflects a broad stress response without a tractable therapeutic window. Support: Mediator kinases regulate normal transcription too. Against: the reported subtype sensitivity argues for selectivity. Human PK\/PD, normal progenitor toxicity, rescue experiments, reproducibility across primary AML samples and efficacy at clinically attainable exposures would discriminate. No clinical response should be inferred.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>AML is a marrow malignancy of immature myeloid cells. CDK8\/19 phosphorylate transcriptional regulators within the Mediator kinase module; venetoclax inhibits antiapoptotic BCL2.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Peer-reviewed preclinical work; no clinical response is reported.<\/li>\n<li>Sensitivity was most pronounced in FLT3-mutant AML.<\/li>\n<li>Combination synergy with venetoclax was tested in vivo in model systems.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>A credible preclinical rationale for CDK8\/19 plus venetoclax in a molecular subset. Human exposure, tolerability and normal-progenitor effects are the next tests.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: moderate-high. Confidence in Interpretation: moderate-low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A peer-reviewed Leukemia paper published online November 11 identifies CDK8\/19 Mediator kinase inhibition as an AML vulnerability and reports preclinical synergy with venetoclax. It does not establish patient efficacy.<\/p>\n","protected":false},"author":1,"featured_media":4232,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[76,1443,1444],"class_list":["post-4217","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-acute-myeloid-leukemia","tag-aml874","tag-cdk8-19"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4217"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4217\/revisions"}],"predecessor-version":[{"id":4250,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4217\/revisions\/4250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4232"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}